Brief: Rubius Therapeutics Inc - Plan To File Investigational New Drug Application By End Of 2020."
22/06/2020 13:48
Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS HIGHLIGHTS PRECLINICAL DATA FOR
RTX-321, A
RED CELL THERAPEUTIC ONCOLOGY PRODUCT CANDIDATE FOR HPV-POSITIVE
CANCERS
* RUBIUS THERAPEUTICS INC - PLAN TO FILE INVESTIGATIONAL NEW
DRUG
APPLICATION BY END OF 2020."
Source text for Eikon: ID:nGNXl7j3X
Further company coverage: RUBY.O
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft